pharmaphorum6y
US regulator backs Pfizer's Vizimpro lung cancer drug
The US drug regulator has given Pfizer’s Vizimpro the green light in a group of lung cancer patients whose tumours have a certain mutation.
pharmaphorum18d
NICE clears front-line NHS use for Pfizer’s lung cancer drug Vizimpro
Pfizer has stolen a march on rival AstraZeneca in the first-line non-small cell lung cancer category, after NICE backed the use of its EGFR inhibitor Vizimpro for NHS use. The once-daily pill will ...